Organization | Brii Biosciences

Brii Biosciences Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: San Francisco CA United States (2017)

Organization Overview

First Clinical Trial

2020

NCT04479631

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Brii Biosciences, Inc. | Brii Biosciences Limited

Active Ingredients

Drugs in Phase 3 Trials (5)

brii-196 (6 trials)

brii-198 (6 trials)

ly3819253 (1 trial)

remdesivir (Veklury) (2 trials)

vir-7831 (1 trial)

Drugs in Phase 2 Trials (5)

brii-179 (1 trial)

brii-296 (1 trial)

interferon alfa-1b (Rebif) (1 trial)

interferon alpha-2a (roferon-a) (1 trial)

vir-2218 (3 trials)

Drugs in Phase 1 Trials (1)

brii-297 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial APIs: 11